By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today announced a deal with Genetics Laboratory to develop and commercialize an assay for the detection of infections in bones and joints.

The assay will be developed for use on Abbott's Plex-ID automated platform for the identification of microbes. The platform is intended for non-diagnostic use only in the US, but assays are being developed for future clinical diagnostic purposes, Abbott said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.